1.Report on recent progress of chronic lymphocytic leukemia in the 53rd annual meeting of American Society of Hematology
Wei WU ; Wei XU ; Jianyong LI
Journal of Leukemia & Lymphoma 2012;21(1):6-9
Chronic lymphocytic leukemia (CLL), the most frequent form of leukemia in Western countries, is characterized by the clonal proliferation and accumulation of neoplastic B lymphocytes in the blood,bone marrow,lymph nodes and spleen.During the past decades,important advances have been made in the understanding of the biology,pathology,diagnosis and treatment of CLL.In the 53rd ASH annual meeting,lots of new discoveries about the biology, prognosis, and treatment of CLL were introduced which lead us to further understand CLL and may provide more or better treatments for CLL patients.
2.Analysis of adverse reactions and complications of Graves' disease after thyroid arteries embolization
Wenquan ZHUANG ; Wei CHEN ; Jianyong YANG
Journal of Interventional Radiology 1994;0(02):-
Objective To retrospectively analyse the adverse reactions and complications of Graves' disease after thyroid arteries embolization.Methods 41 patients of Graves' disease underwent interventional embolization have been analysed with its adverse reactions and complications. Polyvinyl alcohol or bletilla microspheres and micro coils were used in these patients. Results Laryngopharyngeal and neck pain occurred in all patients. T 3 and T 4 increased in 3 days to one week after the procedure. Thirty of them showed fever. Dystopic embolism happened in two cases with one of transitory hypoparathyroidism. No hypothyroidism or hypoparathyroidism or hoarseness occur during long term follow up.Conclusions The adverse reactions and complications of Graves disease after thyroid arteries embolization may occur. Some of them are preventable and curable.
3.Report on recent treatment of Hodgkin' s lymphoma in the 54th ASH annual meeting
Zhijian ZOU ; Wei XU ; Jianyong LI
Journal of Leukemia & Lymphoma 2013;22(1):21-24
Early stage Hodgkin' s lymphoma (HL) is highly curable with abbreviated chemotherapy plus involved-filed radiotherapy or chemotherapy alone,but the role of radiation remains the subject of debate and disagreement.The management of recurrent or refractory HL remains challenging with limited effective treatments except high dose therapy with autologous stem cell transplantation.Emerging new safe and effective drugs such as brentuximab vedotin might promisingly improve the outcome of these patients in the future.The interim positron emission tomography (PET-i) scan has important prognostic value in patients with early and advanced stage HL,especially PET scan after 2 cycles.However,the PET-i guided treatment decisions are not currently recommended outside clinical trials.
4.Treatment progress of follicular lymphoma: reports from the 56th American Society of Hematology annual meeting
Ruize CHEN ; Wei XU ; Jianyong LI
Journal of Leukemia & Lymphoma 2015;24(1):6-8
Follicular lymphoma (FL) is a kind of indolent Non-Hodgkin lymphoma (NHL),which stems from follicle germinal center.A lot of research reported the latest development about treatment of FL in the 56th American Society of Hematology (ASH) annual meeting.Effect of radiotherapy for patients at low stage was determined,while the outcomes of clinical trials in which monoclonal antibody (GA101) in combination with chemotherapy for the advanced stage FL were exciting.In rituximab era,relapsed/refractory FL patients who receive stem cell transplantation could acquire preferable remissions.Several novel drugs (inhibitor of BTK or PI3K) for relapsed/refractory FL played a role of guidepost with the progression of corresponding trials.
5.Treatment progress of diffuse large B cell lymphoma: reports from the 56th American Society of Hematology annual meeting
Tingxun LU ; Wei XU ; Jianyong LI
Journal of Leukemia & Lymphoma 2015;24(1):9-12
Diffuse large B cell lymphoma (DLBCL) is one of the most common non-Hodgkin lymphoma (NHL).Since the appearance of rituximab,the most common first-line therapy is rituximab in combination with chemotherapy.About 70 percent of patients could achieve complete remission (CR) and be cured finally.But one third of patients could not reach CR after frontline treatment or relapse early,especially the elder patients or high risk ones.In the 56th American Society of Hematology (ASH) annual meeting,a plenty of treatments focusing on these patients brought encouraging results,which makes it possible to further improve the CR rate.The progresses in relapse/refractory,high risk and special site DLBCL will be summarized in this paper based on the reports in the 56th ASH annual meeting.
6.Report on the research progress of Hodgkin lymphoma in the 55th ASH annual meeting
Zhijian ZOU ; Wei XU ; Jianyong LI
Journal of Leukemia & Lymphoma 2014;23(1):17-19
The role of consolidating radiation therapy (RT) is very controversial in Hodgkin lymphoma (HL),especially in adolescents and young adults (AYA) HL.The key problem is how to achieve better therapeutic effect but bear less toxicities in chemotherapy and radiotherapy,which will be hopefully solved by clinical trials adopting interim positron emission tomography (iPET) scanning to guide therapy for HL.The new technologies including whole genome amplification (WGA),high-throughput gene sequencing (NGS) assay and genome-wide association study (GWAS) further illustrate abnormal signaling pathways in HL,such as NF-κB,JAK/STAT and PI3K pathway,which may provide new therapeutic targets for the disease.
7.Report on recent treatment of Hodgkin's lymphoma in the 53rd annual meeting of American Society of Hematology
Zhijian ZOU ; Wei XU ; Jianyong LI
Journal of Leukemia & Lymphoma 2012;21(2):70-72
Hodgkin's lymphoma(HL)is a highly curable malignancy for most patients during the recent decades.Frontline treatment is generally ABVD alone or in combination with other chemotherapy regimens or radiation. To achieve a higher control of disease, ABVD chemotherapy has been challenged by more intensive treatments, such as Stanford V and BEACOPP regimen. In the 53rd ASH annual meeting,ABVD is still widely accepted as standard regimen for HL, even in elderly people or patients with HIV infection. Relapsed or refractory HL is a challenging problem for clinician, and high dose chemotherapy followed by autologous stem cell transplantation(HDC/ASCT)is the preferred treatment for chemoresistant patients.Many novel treatment strategies were explored for these patients.Positron emission tomography (PET) scanning provides important prognostic information in patients with HL receiving chemotherapy or pre/posttransplant,but the utility of long term surveillance radiological studies is not recommended in the meeting.
8.Research progress of the prognosis of diffuse large B-cell lymphoma:reports from the 57th American Society of Hematology annual meeting
Xinyu ZHANG ; Wei XU ; Jianyong LI
Journal of Leukemia & Lymphoma 2016;25(2):69-71,74
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma with highly heterogeneous clinical course. How to recognize patients with high risk is coming into the focus of the 57th American Society of Hematology (ASH) annual meeting. The International Prognostic Index (IPI) score as a classic prognostic system is challenged by variety of new prognosis systems. The tumor microenvironment plays an important role in progression of lymphoma, and its prognostic value draw much more attention. The value of PET-CT for prognosis of DLBCL has also been affirmed in this meeting.
9.Progress in treatment of follicular lymphoma
Yingying YUAN ; Jianyong LI ; Wei XU
Journal of Leukemia & Lymphoma 2017;26(1):21-23,27
Follicular lymphoma (FL) is a kind of indolent non-Hodgkin lymphoma (iNHL), which origins from follicle germinal center. Multiple researches reported the latest development about treatment of FL in the 58th American Society of Hematology (ASH) Annual Meeting. The outcomes of clinical trials in which GAl01 combined with chemotherapy and bendamustine in combination with 90Y-ibritumomab tiuxetan for the advanced stage FL were exciting. Relapsed/refractory FL patients who receive tandem autologous followed by nonmyeloablative allogeneic transplantation could acquire preferable remissions. With the emerging of novel drugs including inhibitor of bcl-2 or PI3K and antibody drug conjugate, more and more improvements of efficacy and remission were made in the treatment of relapsed/refractory FL therapy and remission.
10.Report on recent use of PET-CT in lymphoma in the 54th ASH annual meeting
Jiazhu WU ; Wei XU ; Jianyong LI
Journal of Leukemia & Lymphoma 2013;22(1):11-12,16
Positron emission tomography-computed tomography (PET-CT) with both anatomic and functional information is now widely utilized for most lymphoma subtypes,among which,the pretreatment staging and response assessment of PET-CT in Hodgkin lymphoma (HL) and diffuse large B-cell lymphoma (DLBCL)have been well documented.Multiple clinical trials are ongoing using PET-CT for therapy monitoring.Additionally,factors interpreting interim PET (PET-i) like visual analysis using Deauville 5-PS,metabolic tumor volume at baseline (MTV0),and △ SUVmaxPET0-i show different prognostic values.However,the management of PET-CT in lymphoma is still elusive,further trials remain to be done to get evidences for the use of PET-CT in guiding therapeutic decisions.